Paley Front Row 2020 with Gloria Estefan, Tony Gonzalez, George Lopez, Justina Machado, Soledad O’Brien, Edward James Olmos, María Elena Salinas, and Jimmy Smits. The Paley Center’s inaugural Hispanic Heritage Month celebration begins with a conversation among some of most accomplished and influential figures in media today. Paying tribute to Hispanic Achievements in Television across music, drama, sports, news, and comedy, these luminaries will discuss the state of this thriving industry, the bright future ahead, and their own successful journeys.
A 3-Michelin star restaurant in Napa has burned down in California’s latest wildfire
Restaurant at Meadowood, a Napa Valley restaurant with three Michelin stars, has burned to the ground in California’s latest wildfire.
The world-famous restaurant was consumed by the Glass Fire on Monday morning.
A spokesperson for the Restaurant at Meadowood’s parent company said the restaurant will be rebuilt and reopen.
Glass Fire has destroyed seven wineries and burned more than 42,000 acres as of Tuesday morning.
Visit Insider’s homepage for more stories.
A Napa restaurant with three Michelin stars has burned down as California continues to fight against raging wildfires.
All that remains of the Restaurant at Meadowood — also known as TRAM — is two brick fireplaces and the stone stairs at the entrance.
It burned down in the Glass Fire, which has destroyed seven wineries and burned more than 42,000 acres as of Tuesday morning, according to Cal Fire’s latest incident report.
Chef Christopher Kostow, TRAM’s head chef, confirmed the loss of his restaurant with an Instagram post on Monday night.
“We are all torn apart,” Kostow’s caption read. “A Euology is deserved, and will be given in due time. For now, I want to thank all of the TRAMily that have ever graced this magical space — and all of the guests over the years who have enjoyed the efforts of these multitudes. What an honor it has been.”
The restaurant has plans to rebuild
Kostow told Insider he has “no doubt” that Napa Valley will “rebuild and come back stronger than ever.”
“Napa Valley and California have seen their share of challenges and have always demonstrated a resiliency that others emulate,” he said. “The important thing right now is to protect lives and property, and address the bigger issue of climate change.”
Guests and staff at Meadowood, the five-star luxury resort where TRAM was located, were evacuated from the 250-acre property on Sunday, according to the East Bay Times.
The Glass Fire reached Meadowood around 3 a.m. on Monday morning, Brett Anderson, a spokesperson for the resort’s parent company, told the paper.
TRAM was already engulfed in flames when firefighters arrived on the scene, Capt. Matt Dowland told ABC 7.
“We were able to put it out [but] unfortunately the water system, the tanks, got destroyed and then we ran out of water,” Dowland added.
Firefighters drained the resort’s swimming pool to access more water, but TRAM couldn’t be salvaged.
Parts of the resort still stand, but Anderson told CBS San Francisco that the Meadowood team was “heartbroken” to lose its legendary restaurant.
Anderson said it wouldn’t be the end of TRAM’s legacy, however, adding that the Harlan family, which has owned Meadowood for six decades, already had plans to rebuild it.
“We’re going to reopen,” he told the site. “And we believe that the Napa Valley, as it has in the past, will experience a renaissance after this.”
The fire that burned down TRAM — called the Glass Fire — has already burned 11,000 acres in Napa Valley
The Glass Fire has wreaked havoc in Napa Valley with unprecedented speed, torching 11,000 acres in just 24 hours after it began around 3:50 a.m. on Sunday, according to the Cal Fire incident report.
By Monday morning the fire had jumped from the east to the west side of the valley, shocking many residents and business owners who thought they were a safe distance away from the flames, according to CBS San Francisco.
Among them was Dario Sattui, owner of the famous Castello di Amorosa Winery. The fire engulfed the winery’s storage building, destroying millions of dollars worth of bottled wine.
“I should have stayed up all night, I didn’t think the fire would jump Highway 29,” Sattui told ABC 7. “The lab is gone, offices are gone, the wine was destroyed.”
The Glass Fire has also devastated the Chateau Boswell Winery in St. Helena and the nearby Black Rock Inn, according to The San Francisco Chronicle.
More than 68,000 people have been forced to evacuate Napa Valley and Sonoma County. The fire was 0% contained as of Tuesday morning.
“It’s like God has no sympathy, no empathy for Sonoma County,” Sonoma County Supervisor Susan Gorin told the Chronicle after evacuating her home.
Wildfires continue to destroy millions of acres in California
There are currently 27 major active wildfires burning across California. 26 people have been killed and 7,000 buildings destroyed since mid-August from the fires.
Over 3.7 million acres have been burned in the state since the start of 2020. By comparison, just under 260,000 acres were burned in 2019.
Read the original article on Insider
Apple grants CEO Tim Cook first major stock package since 2011
Oppenheimer: These 2 Stocks Are Poised to Surge by Over 100%
When it comes to the market’s wild swings, is the glass half empty or half full? Oppenheimer’s chief investment strategist John Stoltzfus is taking the latter view.Despite the volatility that has ruled the market over the last few weeks, Stoltzfus actually likes what he’s witnessing in both the market and the economy. In particular, he points to U.S. companies that have been outperforming most other markets around the world as exciting plays, with the innovation in the U.S. reflecting a key component of his bullish thesis.“The U.S. is outperforming most of the markets around the world — whether it’s developed markets or emerging markets… We’ve taken out the froth that had come into the market in certain [mega cap] names. It may be a good opportunity to pick up some really good, high quality growth stories that are on sale right now,” Stoltzfus noted.Additionally, the strategist believes the S&P 500 could climb back to its September 2 high point, based on improving economic data. The approval of a COVID-19 vaccine as well as an election outcome that is “friendly to the domestic economy, business, job growth and the taxpayer” could also push the index higher.Turning Stoltzfus’ outlook into tangible recommendations, Oppenheimer analysts are pounding the table on two stocks, with these pros seeing over 100% upside potential in store. Running the tickers through TipRanks’ database, we wanted to find out exactly what makes them so compelling.Brickell Biotech (BBI)Focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases, Brickell Biotech wants to improve the lives of patients everywhere. Given the potential of the company’s lead candidate and its $0.82 share price, Oppenheimer thinks that now is the time to pull the trigger.Sofpironium bromide (SB), a prescription treatment for axillary hyperhidrosis (AH, or excessive underarm sweating), is entering U.S. Phase 3 trials. This program will consist of two identical six-week studies, and will evaluate its ability to improve the condition per the objective (gravimetric sweat production) and subjective (HDSM-Ax) co-primary endpoints. Each is expected to last 12 months, and the first will kick off next quarter.Roughly 10 million people in the U.S. suffer from AH, with this condition interfering with daily social and professional activities. Currently, only 2.3 million receive prescription treatment, and some resort to invasive or permanent interventions like Botox, MiraDry or surgery.Oppenheimer’s Leland Gershell argues that more conservative approaches could be used to meet these medical needs. He also believes the recent entry of Eli Lilly’s competing product, Qbrexza, represents a significant step forward. That said, there’s “room for improvement” with this anti-cholinergic approach.Looking at a U.S. Phase 2b trial, the highest dose of BBI’s SB gel (15%) demonstrated 46% greater sweat reduction per gravimetric analysis compared to the placebo, with significant reductions in a validated patient-reported outcome instrument seen at all doses. Based on the trial data, efficacy is over 50% better than Qbrexza per label, despite higher baseline severity. In addition, their safety profiles were relatively similar.It should be noted that BBI will market the drug to U.S. dermatologists through a specialty salesforce of 120 representatives. According to Gershell’s estimates, uptake by 110,000 patients per year (just 5% of the currently treated AH population) translates to $200 million in gross sales. The analyst adds that patent issuance could extend market exclusivity to 2040.Adding to the good news, on September 25, BBI announced that Kaken Pharmaceutical, its development partner, got the green light to manufacture SB in Japan for the treatment of AH. Japan is the first country to approve the candidate, with the launch expected later this year.To sum it all up, Gershell stated, “By virtue of its efficacy, tolerability, and antiperspirant-like application, we believe SB offers an attractive profile in a market that offers much room for improved solutions. We encourage risk-tolerant investors to build a position ahead of upcoming newsflow.”To this end, Gershell rates BBI an Outperform (i.e. Buy) along with a $5 price target. This target conveys the analyst’s confidence in BBI’s ability to surge 502% from current levels. (To watch Gershell’s track record, click here)Looking at the consensus breakdown, 2 Buys and no Holds or Sells have been published in the last three months. As a result, BBI gets a Moderate Buy consensus rating. The $5 average price target is identical to Gershell’s. (See BBI stock analysis on TipRanks)Aldeyra Therapeutics (ALDX)As for Oppenheimer’s other pick, Aldeyra Therapeutics works to bring new treatment options for immune-related diseases to market. Based on the solid progress of its pipeline, the firm has high hopes for this healthcare name.Representing Oppenheimer, analyst Justin Kim points out that he came away from a recent conversation with the CEO even more confident in ALDX’s long-term growth prospects. Pivotal studies on reactive aldehyde species (RASP) are slated for Q4 2020, evaluating the action of reproxalap, Aldeyra’s lead therapy designed to clamp down on overactive inflammation, on tear levels of RASP over a period ranging from 1-2 days to 28 days. “Based on Phase 2a results, we are confident in the ability to replicate results in Q4 2020,” Kim stated.Given the potential of dry eye disease (DED) in the near-term, the analyst expects significant investor focus to land on clinical trial execution (Phase 3 RASP studies and safety study), which would support a potential NDA filing by the end of 2021, in Kim’s opinion. “Despite some volatility in the shares, we see a solid setup emerging as the company initiates its Phase 3 RASP studies in dry eye disease (DED),” he said.Speaking to the potential of RASP as an accepted dry eye endpoint, ALDX has experienced “a watershed moment,” with it facilitating an expedited path to registration (from traditional sign endpoints) and greater likelihood of clinical trial success, based on reproxalap’s mechanism of action (MoA) as a RASP-trap, according to Kim.He added, “Moreover, agreement on RASP could have broader implications for a commercial launch in dry eye, a market that we believe will see segmentation as more therapies with targeted MoAs become incorporated into the armamentarium.”“We continue to be impressed by the progress in achieving a potential concurrent filing for dry eye and allergic conjunctivitis (AC), appreciating the importance of a differentiated dry eye agent with action also in AC. As the dry eye therapeutic landscape increases its options, we expect greater segmentation of the heterogeneous patient population potentially beginning with reproxalap’s positioning in ‘allergic dry eye’,” the analyst concluded. For the rest of 2020, focus is likely to stay on Phase 3 study designs (assay work/development), execution and the potential readout in DED, which could set the stage for a commercial launch in DED and AC in 2022.If that wasn’t enough, based on the broader pipeline of candidates targeting PVR, inflammatory conditions and COVID-19, Kim sees “a rich environment of catalysts for the shares over the coming 12-18 months.”It should come as no surprise, then, that Kim stayed with the bulls. To this end, he kept an Outperform rating and $15 price target on the stock. Investors could be pocketing a gain of 110%, should this target be met in the twelve months ahead. (To watch Kim’s track record, click here)What does the rest of the Street have to say? Only Buy ratings, 2 to be exact, have been issued in the last three months. So, the consensus rating is a Moderate Buy. In addition, the $23.50 average price target suggests 227% upside potential from current levels. (See ALDX stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
A new SpaceX video shows never-before-seen footage of its first astronaut flight
SpaceX released a video on Tuesday that chronicles its Demo-2 mission, the first crewed flight of its Crew Dragon spaceship. The mission carried NASA astronauts Doug Hurley and Bob Behnken to and from the International Space Station, and it went remarkably smoothly – an outcome that felt somewhat out-of-keeping with this turbulent year on Earth.
“We hope it brings a little bit of brightness to a pretty tough 2020,” Hurley says at the end of the video.
The never-before-broadcast footage shows Behnken and Hurley driving to the launch site at the Kennedy Space Center in Cape Canaveral, Florida. After giving thumbs-ups to onlookers, the two astronauts board the Crew Dragon.
“Three…two…one…ignition, liftoff,” Mission Control says. Then SpaceX’s Falcon-9 rocket ignites.
Once they enter space, Behnken does a backflip as a stuffed sequined dinosaur floats around the capsule. “Tremor the Apatosaurus” was the latest in a long line of stuffed animals that astronauts have brought into space as zero-gravity indicators; when the toys start to float, observers know the ship has entered microgravity.
The video also shows the moments after Crew Dragon docked with the space station, when the astronauts met up with the members of Expedition 63. The montage ends with their return to Earth: A small white capsule shrieks through the atmosphere, then its parachutes deploy, slowing it to a gentle splashdown in the Gulf of Mexico.
You can watch the full video below:
SpaceX is learning from Demo-2 to make its next mission smoother
As test missions go, Demo-2 was remarkably hassle-free.
“The greatest surprise is that this mission was as smooth as it is,” Gwynne Shotwell, SpaceX’s president and COO, said after Behnken and Hurley’s splashdown.
Still, the mission wasn’t without snags. For instance, once the Crew Dragon landed, its thrusters began emitting toxic fumes. Throngs of boats carrying tourists and onlookers also ignored commands to keep their distance.
These problems serve as learning opportunities for NASA and SpaceX as they prepare for the next crewed mission in their partnership, Crew-1. That’s scheduled to launch at 2:40 a.m. ET on October 31.
That crew includes NASA astronauts Shannon Walker, Mike Hopkins, and Victor Glover, as well as Japan Aerospace Exploration Agency astronaut Soichi Noguchi. Hopkins is slated to be the mission’s commander, Glover the pilot, and Walker and Noguchi mission specialists.
The Demo-2 astronauts have already offered some words of wisdom for that group. Hopkins said Hurley warned him about the shocking speed of re-entering the Earth’s atmosphere.
“His comment about entry was, ‘It happens fast,'” Hopkins said in a press briefing on Tuesday. “From the time the de-orbit sequence starts, the entry sequence starts, to when you touch down is very fast.”
“For me, that means I need to make sure that we, as a crew, are ready for it,” Hopkins added. “When things happen fast, you need to be anticipating.”
But minor issues and surprises aside, NASA and SpaceX officials are mostly hoping for a repeat of Demo-2’s success later this fall.
“It will be a great mission if Crew-1 goes exactly the same way,” Kathy Lueders, NASA’s head of human spaceflight, said during the Tuesday briefing. “I’m counting on a beautiful mission.”
Read the original article on Business Insider
- California bans super-toxic rat poisons that killed wild animals
- Jimmy Butler weighs in on why Heat has been good fit compared to Sixers
- A 3-Michelin star restaurant in Napa has burned down in California’s latest wildfire
- Apple grants CEO Tim Cook first major stock package since 2011
- ‘Truthful’ Luke Voit better suited for this Yankees playoff role
- Who Biden and Trump invited as symbolic guests to presidential debate
- Cuomo planning to cut $300M from state courts system: memo
- Will NFL season continue as scheduled? Titans’ COVID-19 outbreak is test
- A new SpaceX video shows never-before-seen footage of its first astronaut flight
- Why Clare Bronfman won’t disavow Nxivm’s Keith Raniere
Sports News5 days ago
US Olympian Chloe Dygert crashes over guardrail in cycling accident
Entertainment1 week ago
Danish TV show ‘Ultra Strips Down’ records kids eyeing naked adults
Sports News4 weeks ago
Fantasy Football Auction Draft strategy: Tips, advice for spending your 2020 player budget wisely
Sports News3 weeks ago
NBA 2K21 Cover Star Damian Lillard Reveals His Issues With the Game
Tech1 week ago
iOS 14 basics: how to add widgets to your iPhone’s home screen
Sports News1 week ago
Fantasy Football Buy-Low, Sell-High Stock Watch: Leonard Fournette, Stefon Diggs among movers heading into Week 3
Sports News3 weeks ago
NBA playoff bracket 2020: Updated standings, seeds & results from each round
Sports News3 weeks ago
NFL Analyst Takes a Cheeky Dig on Browns Stars Odell Beckham Jr. and Baker Mayfield